PL375741A1 - Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin - Google Patents
Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietinInfo
- Publication number
- PL375741A1 PL375741A1 PL03375741A PL37574103A PL375741A1 PL 375741 A1 PL375741 A1 PL 375741A1 PL 03375741 A PL03375741 A PL 03375741A PL 37574103 A PL37574103 A PL 37574103A PL 375741 A1 PL375741 A1 PL 375741A1
- Authority
- PL
- Poland
- Prior art keywords
- long acting
- tissue protective
- protective activity
- maintain tissue
- endogenous erythropoietin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/10—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using coupling agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Toxicology (AREA)
- Psychiatry (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40902002P | 2002-09-09 | 2002-09-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
PL375741A1 true PL375741A1 (en) | 2005-12-12 |
Family
ID=31978712
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL03375741A PL375741A1 (en) | 2002-09-09 | 2003-09-09 | Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP1545586A4 (zh) |
JP (1) | JP2006511468A (zh) |
KR (1) | KR20050083682A (zh) |
CN (2) | CN101371920A (zh) |
AU (1) | AU2003273297A1 (zh) |
BR (1) | BR0314152A (zh) |
CA (1) | CA2497960A1 (zh) |
EA (1) | EA007812B1 (zh) |
IL (1) | IL174178A0 (zh) |
IS (1) | IS7731A (zh) |
MX (1) | MXPA05002617A (zh) |
NO (1) | NO20051714L (zh) |
PL (1) | PL375741A1 (zh) |
WO (1) | WO2004022577A2 (zh) |
ZA (1) | ZA200505423B (zh) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7718363B2 (en) | 2003-04-25 | 2010-05-18 | The Kenneth S. Warren Institute, Inc. | Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds |
WO2006061853A2 (en) * | 2004-12-10 | 2006-06-15 | Serum Institute Of India Limited | Novel erythropoietic compounds and a process for producing erythropoietic compounds |
TWI376234B (en) | 2005-02-01 | 2012-11-11 | Msd Oss Bv | Conjugates of a polypeptide and an oligosaccharide |
IN2014CN02050A (zh) | 2005-08-05 | 2015-05-29 | Araim Pharmaceuticals Inc | |
ES2539124T3 (es) | 2008-01-22 | 2015-06-26 | Araim Pharmaceuticals, Inc. | Péptidos y análogos peptídicos protectores de tejido para la prevención y el tratamiento de enfermedades y trastornos asociados con daño tisular |
CN101671388B (zh) * | 2008-09-09 | 2013-01-02 | 曹国栋 | 血脑屏障穿透性促红细胞生成素及其应用 |
RU2475273C1 (ru) * | 2012-04-02 | 2013-02-20 | Юлия Николаевна Козлова | Способ получения полимерного цемента медицинского назначения |
CN102746405B (zh) * | 2012-07-24 | 2013-08-21 | 深圳赛保尔生物药业有限公司 | 重组人促红素的连续聚乙二醇化反应方法 |
RU2664588C2 (ru) * | 2015-11-05 | 2018-08-21 | Закрытое Акционерное Общество "Биокад" | Пролонгированный фактор эритропоэза человека и лекарственное средство на его основе |
CN109310741A (zh) | 2016-04-29 | 2019-02-05 | 阿拉伊姆药品公司 | 用于预防和治疗与组织损伤相关的疾病和障碍的组织保护肽 |
CN112741895A (zh) * | 2021-01-19 | 2021-05-04 | 中国人民解放军陆军军医大学 | Epo类似物在制备治疗脓毒症药物中的应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20010288A1 (es) * | 1999-07-02 | 2001-03-07 | Hoffmann La Roche | Derivados de eritropoyetina |
CA2406807C (en) * | 2000-04-21 | 2010-04-06 | Amgen Inc. | Methods and compositions for the prevention and treatment of anemia |
HU230874B1 (hu) * | 2000-05-15 | 2018-11-29 | F. Hoffmann-La Roche Ag | Pegilezett humán eritropoietin-fehérjét tartalmazó, szobahőmérsékleten stabil folyékony gyógyászati készítmények |
-
2003
- 2003-09-09 EP EP03755796A patent/EP1545586A4/en not_active Withdrawn
- 2003-09-09 PL PL03375741A patent/PL375741A1/xx not_active Application Discontinuation
- 2003-09-09 MX MXPA05002617A patent/MXPA05002617A/es unknown
- 2003-09-09 ZA ZA200505423A patent/ZA200505423B/xx unknown
- 2003-09-09 WO PCT/US2003/028073 patent/WO2004022577A2/en active Application Filing
- 2003-09-09 BR BR0314152-7A patent/BR0314152A/pt not_active IP Right Cessation
- 2003-09-09 EA EA200500473A patent/EA007812B1/ru not_active IP Right Cessation
- 2003-09-09 CN CNA2008101490873A patent/CN101371920A/zh active Pending
- 2003-09-09 JP JP2004534745A patent/JP2006511468A/ja not_active Withdrawn
- 2003-09-09 CA CA002497960A patent/CA2497960A1/en not_active Withdrawn
- 2003-09-09 AU AU2003273297A patent/AU2003273297A1/en not_active Abandoned
- 2003-09-09 KR KR1020057004045A patent/KR20050083682A/ko not_active Application Discontinuation
- 2003-09-09 CN CNA038249154A patent/CN1729015A/zh active Pending
-
2005
- 2005-03-08 IS IS7731A patent/IS7731A/is unknown
- 2005-04-06 NO NO20051714A patent/NO20051714L/no not_active Application Discontinuation
-
2006
- 2006-03-08 IL IL174178A patent/IL174178A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN101371920A (zh) | 2009-02-25 |
EP1545586A4 (en) | 2007-09-26 |
AU2003273297A1 (en) | 2004-03-29 |
ZA200505423B (en) | 2008-08-27 |
KR20050083682A (ko) | 2005-08-26 |
JP2006511468A (ja) | 2006-04-06 |
IS7731A (is) | 2005-03-08 |
IL174178A0 (en) | 2006-08-01 |
AU2003273297A8 (en) | 2004-03-29 |
EA200500473A1 (ru) | 2005-10-27 |
EP1545586A2 (en) | 2005-06-29 |
BR0314152A (pt) | 2005-07-12 |
WO2004022577A3 (en) | 2004-09-16 |
CA2497960A1 (en) | 2004-03-18 |
MXPA05002617A (es) | 2005-09-08 |
CN1729015A (zh) | 2006-02-01 |
EA007812B1 (ru) | 2007-02-27 |
WO2004022577A2 (en) | 2004-03-18 |
NO20051714L (no) | 2005-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL174178A0 (en) | Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin | |
PL377514A1 (pl) | Pochodne benzoazolilopiperazyny o działaniu antagonistycznym wobec VR1 | |
ATE338577T1 (de) | Sprühbares hautschutzmittel | |
IL159439A0 (en) | Iodobenzopyran-4-one derivatives having fungicidal activity | |
IL157456A0 (en) | Aryl and biaryl compounds having mch modulatory activity | |
DE69900038D1 (de) | Kosmetische oder dermatologische Zubereitung | |
EP1555957A4 (en) | CLOSURE FOR SKIN AND OTHER TISSUE | |
HK1085375A1 (en) | Topical skin and/or hair compositions containing an hydrolysed protein | |
EP1575528A4 (en) | TREATMENT PROTECTIVE CYTOKINS FOR THE PROTECTION, RECOVERY AND STRENGTHENING OF RESPECTIVE CELLS, TISSUE AND ORGANS | |
AU2003298837A8 (en) | Prolonged suppression of electrical activity in excitable tissues | |
EP1534353A4 (en) | ORTHOPEDIC MATERIALS DERIVED FROM KERATIN | |
AU2003241291A8 (en) | Vascularized human skin equivalent | |
AU2003276129A1 (en) | Compositions and methods for darkening the skin | |
HK1064289A1 (en) | External skin preparation | |
AU2003288971A8 (en) | Compositions for darkening the skin and/or hair | |
AU2003230566A8 (en) | Therapeutic regulation of deoxyribonuclease-1-like-3 activity | |
DE60030175D1 (de) | Automatenlegierung | |
TW510160U (en) | Structure of clippers for gardening use | |
AU152831S (en) | Hair trimmer | |
AU2003299660A8 (en) | Wound and skin care compositions | |
AU2003220567A8 (en) | Compostions for darkening the skin | |
AU2003288972A8 (en) | Compositions for darkening the skin and/or hair | |
AU2003297282A8 (en) | Protection of cardiac myocardium | |
EP1570838A4 (en) | DENDRIT EXTENSION INHIBITOR FOR MELANOZYT AND SKIN PREPARATION FOR EXTERNAL USE, INCLUDING THAT SAME. | |
AU2003239844A8 (en) | Bioartificial skin comprising genetically modified fibroblasts |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |